MiR-23a-3p acts as an oncogene and potential prognostic biomarker by targeting PNRC2 in RCC.

CONCLUSIONS: Our results reveals that miR-23a-3p may not only serve as a new biomarker for prognosis but also serve as a new therapeutic strategy in the RCC treatment.
PMID: 30551118 [PubMed - as supplied by publisher]

Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - December 11, 2018 Category: Drugs & Pharmacology Authors: Quan J, Pan X, Li Y, Hu Y, Tao L, Li Z, Zhao L, Wang J, Li H, Lai Y, Zhou L, Lin C, Gui Y, Ye J, Zhang F, Lai Y Tags: Biomed Pharmacother Source Type: research